Instruction for use: Tonsilgon N

Dosage form: Pills; Drops for oral administration

ATX

R02AA20 Other drugs

Pharmacological group:

Antiseptic agent of vegetable origin [Other immunomodulators in combinations]

The nosological classification (ICD-10)

J02.9 Acute pharyngitis, unspecified: Purulent pharyngitis; Acute rhinopharyngitis; Lymphonodular pharyngitis

J03.9 Acute tonsillitis, unspecified (angina agranulocytic): Throat infections; Acute tonsillitis; Angina; Follicular tonsillitis; Angina alimentary-hemorrhagic; Secondary sore throat; Sore throat primary; Angina follicular; Angina; Inflammatory diseases of the tonsils; Catarrhal angina; Lacunar angina; Acute Sore Throat; Tonsillitis; Tonsillitis acute; Tonsillar angina; Follicular sore throat; Bacterial tonsillitis

J04 Acute laryngitis and tracheitis: Cough in diseases of the upper respiratory tract; Laryngitis; Laryngitis acute; Tracheitis acute; Pharyngolaryngitis; Infectious-inflammatory disease of ENT organs

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J31.2 Chronic pharyngitis: Pharyngitis chronic; Exacerbation of inflammatory diseases of the pharynx and oral cavity; Hypertrophic pharyngitis; Inflammatory process of pharynx; Sore Throat Infection; Infectious-inflammatory diseases of the pharynx; Infectious-inflammatory diseases of the oral cavity and pharynx; Atrophic pharyngitis

J35.0 Chronic tonsillitis: chronic tonsillitis; Inflammatory diseases of the tonsils; Angina chronic; Chronic hypertrophic tonsillitis; Tonsillar angina

J37.0 Chronic laryngitis: Chronic atrophic laryngitis

Z29.1 Prophylactic immunotherapy: Vaccination against viral infections; donor Vaccination; Vaccination and revaccination; Vaccination of newborns; Vaccination against hepatitis B; Immunization; Correction of the immune status; Therapeutic and prophylactic immunization; Preventive immunization; Specific immunoprophylaxis; Stimulation of the processes of nonspecific immunit

Composition

Dragee - 1 dragee

Active substances:

Althaea roots 8 mg

Chamomile flowers 6 mg

Horsetail herb 10 mg

Walnut leaves 12 mg

Yarrow herb 4 mg

Oak bark 4 mg

Dandelion medicinal herb 4 mg

Auxiliary substances: lactose; Maize starch; potato starch; Stearic acid; Glucose monohydrate; Highly disperse silicon dioxide

Shell: calcium carbonate; A glucose syrup; Indigotine; Maize starch; Modified maize starch; Montane glycol wax; PVP K25; PVP K30; Castor oil; Sucrose; shellac; talc; Highly disperse silicon dioxide; Titanium dioxide

Drops for ingestion 100 g

Water-alcohol extract 29 g

Active substances:

Althaea roots 0.4 g

Chamomile flowers 0.3 g

Horsetail grass 0.5 g

Walnut leaves 0.4 grams

Yarrow herb 0.4 g

Oak bark 0.2 grams

Dandelion medicinal herb 0.4 g

Excipients: purified water - 71 g

Description of dosage form

Dragee: biconvex, round in shape, light blue.

Drops for ingestion: a clear or slightly turbid liquid of a yellowish brown color with a characteristic smell of chamomile; There may be a slight deposit during storage.

Pharmachologic effect

Mode action - anti-inflammatory, increasing nonspecific resistance of the body, antiseptic.

Pharmacodynamics

Pharmacological properties are due to the biologically active substances that make up the drug. Tonzylgon® H has anti-inflammatory and antiseptic properties. The active components of chamomile, althaea and horsetail included in the preparation contribute to an increase in the activity of nonspecific factors of body defense. Polysaccharides, essential oils and flavonoids of chamomile, althea and yarrow, tannins of the oak bark have an anti-inflammatory effect and contribute to reducing edema of the mucous membrane of the respiratory tract.

Indications for the preparation Tonsilgon N

Acute and chronic diseases of the upper respiratory tract (tonsillitis, pharyngitis, laryngitis);

Prevention of complications in respiratory viral infections;

As a supplement to antibiotic therapy for bacterial infections of the upper respiratory tract.

Contraindications

Hypersensitivity to the components of the drug, incl. Plants of the family of Compositae;

Lactose intolerance, fructose, lactase deficiency, sucrose-isomaltase, glucose-galactose malabsorption (for dragees);

Children's age (for drops - up to 1 year, for dragees - up to 6 years);

Alcoholism, incl. After antialcohol treatment (for drops).

With caution (for drops): liver disease, TBI, brain disease, children age over 1 year (use is possible only after consulting a doctor in connection with the content of ethyl alcohol in the drug).

Application in pregnancy and breastfeeding

The use of the drug is possible if the potential benefit to the mother exceeds the potential risk to the fetus and the baby. Consultation of the doctor is necessary.

Side effects

From the gastrointestinal tract: nausea and vomiting are possible.

Allergic reactions: possible; When symptoms appear, stop taking the drug.

Interaction

Combination with antibacterial drugs is possible and expedient. Interaction with other drugs is not described.

Dosing and Administration

Inside.

Dragee. Swallow whole, do not liquid, if necessary, wash down with water.

In the acute period of the disease: adults - 2 pills 5-6 times a day; Children of school age (over 6 years) - 1 dragee 5-6 times a day.

After the disappearance of acute symptoms of the disease (sore throat) should continue treatment with the drug for another 1 week: adults - 2 tablets 3 times a day; Children of school age (over 6 years) - 1 tablet 3 times a day.

Drops. Take in undiluted form, holding it in your mouth for a while before swallowing.

In the acute period of the disease: adults - 25 drops 5-6 times a day; Children of school age (over 6 years) - 15 drops 5-6 times a day; Children of preschool age (over 1 year) - 10 drops 5-6 times a day.

After the disappearance of acute symptoms of the disease (sore throat) should continue treatment with the drug for another 1 week: adults - 25 drops 3 times a day; Children of school age (over 6 years) - 15 drops 3 times a day; Preschool age (over 1 year) - 10 drops 3 times a day.

Overdose

To date, cases of overdose have not been documented.

Symptoms: may increase the side effects of the gastrointestinal tract.

Treatment: symptomatic.

Special instruction

If the symptoms persist for 7 days or the patient's condition worsens, consult a doctor.

One dragee contains less than 0.03 XE.

The content of ethyl alcohol in the preparation (drop) is from 16 to 19.5% in volume ratio. In the maximum single dose (25 drops), the absolute ethyl alcohol content is 0.21 g; In the maximum daily dose (25 drops 6 times a day) - 1.26 g.

During the storage of the drug in the form of drops, a slight cloudiness or loss of a slight precipitate is possible, which does not affect the effectiveness of the preparation. Before use, the preparation should be shaken! When using the vial, hold it with the drip device down in the upright position.

Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions

Dragee. The use of the drug does not affect the ability to perform potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Drops. During the period of application of the drug, care should be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions in connection with the content of ethyl alcohol in it.

Release form

Dragee. In aluminum foil blisters (bottom part) and PVC / PVDC films (top), 25 pcs. Each. In the box is a cardboard folding 2 or 4 blisters.

Drops for oral administration. In bottles of dark glass with a volume of 50 or 100 ml with a metering drip device on top, with a screw cap and a safety ring, 50 or 100 ml each. In the carton folding box 1 fl.

Manufacturer

Bionoric CE. Kerschensteiner Straße, 11-15, 92318, Neumarkt, Germany.

The organization that accepts customer claims: Bionorica LLC. 119619, Moscow

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Tonsilgon N

In dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Tonsilgon N

Drops for oral administration - 2 years.

Pills - 3 years.

Pills - 3 years.

Do not use after the expiry date printed on the package.